NanoViricides IncNYSE American:NNVC
- LAST PRICE1.1100
- TODAY'S CHANGE (%)-0.0100 (-0.8929%)
- Bid / Lots1.1100/ 32
- Ask / Lots1.1600/ 1
- Open / Previous Close1.2000 / 1.1200
- Day Range
- 52 Week Range
- Volume11,287
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NNVC |
|---|---|---|
| 09:32 ET | 1205 | 1.2 |
| 09:34 ET | 175 | 1.14 |
| 09:45 ET | 100 | 1.2 |
| 09:50 ET | 626 | 1.165 |
| 10:33 ET | 209 | 1.15 |
| 11:22 ET | 600 | 1.16 |
| 01:03 ET | 100 | 1.13 |
| 01:12 ET | 800 | 1.13 |
| 01:21 ET | 1000 | 1.11 |
| 01:37 ET | 1015 | 1.14 |
| 02:31 ET | 2000 | 1.14 |
| 03:48 ET | 100 | 1.11 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NanoViricides Inc | 13.2M | -1.4x | --- |
Check Cap Ltd | 13.2M | -0.7x | --- |
Purple Biotech Ltd | 13.4M | -0.6x | --- |
Microbot Medical Inc | 12.8M | -0.8x | --- |
Kiora Pharmaceuticals Inc | 12.7M | -0.2x | --- |
Mira Pharmaceuticals Inc | 12.6M | -1.0x | --- |
Company Information
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.
Contact Information
- Headquarters
- 1 Controls DriveSHELTON, CT, United States 06484
- Phone
- 203-937-6137
- Fax
- 203-859-5095
Executives
- President, Chief Executive Officer, Executive Chairman of the Board
- Anil Diwan
- Chief Financial Officer
- Meeta Vyas
- Independent Director
- Makarand Jawadekar
- Independent Director
- Theodore Rokita
- Independent Director
- Brian Zucker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-0.80 |
Book Value | $1.27 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
